2024
Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy
Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, Sprenkle P, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39521675, DOI: 10.1016/j.urolonc.2024.10.018.Peer-Reviewed Original ResearchMRI-TRUSMRI-TRUS fusionImage-guided biopsyFusion biopsyGG upgradingTRUS biopsyBiopsy strategyBiopsy typeNo significant differencePathological concordanceBiopsy techniqueHigh-resolution micro-ultrasoundMRI-TRUS fusion biopsyMultivariate logistic-regression analysisMRI fusion biopsySystematic transrectal ultrasoundProstate cancer patientsSignificant differenceMicro-ultrasoundLogistic-regression analysisMultivariable-analysisPathological downgradingPathological upgradingRandomized controlled trialsProstate biopsyRisk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.Peer-Reviewed Original ResearchGleason score upgradingProstate-specific antigenRisk factorsMagnetic resonance imagingRadical prostatectomyScore upgradingAssociated with Gleason score upgradingBiopsy to radical prostatectomyHigher-risk prostate cancerPatients treated with surgeryProstate magnetic resonance imagingClinically localized diseaseGleason grade groupLow-risk diseaseRecognition of risk factorsBody mass indexGleason upgradingFinal pathologyProstate volumeProstate biopsySource of diagnostic uncertaintyBiopsy coresLocalized diseaseProstate cancerInitial managementThe effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy
Lokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.Peer-Reviewed Original ResearchConceptsEnd-of-studyProstate cancerRadical prostatectomyTreatment armsDouble-blind randomized trialProstate cancer characteristicsSurgical margin statusLocalized prostate cancerFACT-P scoresBaseline to end-of-studySerum PSACAPRA scoreGleason scorePSA levelsPlacebo-controlledMedium-chain triglyceridesPrimary endpointIntermediate riskClinical stageMargin statusSerum testosteroneRandomization armFACT-PRisk strataITT analysisMP58-01 A RANDOMIZED CONTROLLED TRIAL OF A FERMENTED SOY BEVERAGE AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMY
Lokeshwar S, Choksi A, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Brito J, Renzulli J, Leapman M. MP58-01 A RANDOMIZED CONTROLLED TRIAL OF A FERMENTED SOY BEVERAGE AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMY. Journal Of Urology 2024, 211: e947. DOI: 10.1097/01.ju.0001008852.83523.41.01.Peer-Reviewed Original ResearchA0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative study
Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Brito J, Renzulli J, Sprenkle P, Michael M. A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative study. European Urology 2024, 85: s1101. DOI: 10.1016/s0302-2838(24)00884-4.Peer-Reviewed Original ResearchAssociation between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy
Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.Peer-Reviewed Original ResearchPelvic lymph node dissectionBenefit of pelvic lymph node dissectionGleason grade groupLymph node dissectionProstate cancer patientsRadical prostatectomyNode dissectionProstate cancer treated with radical prostatectomyCancer patientsAssociated with improved OSTime of radical prostatectomyGrade groupSurvival of prostate cancer patientsMedian PSA valuePre-operative characteristicsProstate cancer-specificTime of RPLog-rank testKaplan-Meier curvesPSA valuesSurvival benefitProstate cancerMedian ageClinical benefitCancer-specific
2023
Management strategies for radio-recurrent prostate cancer: a comprehensive review
Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2023, 0: 0-0. DOI: 10.21037/tcr-24-245.Peer-Reviewed Original Research
2020
PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy
Abello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy. European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.Peer-Reviewed Original ResearchMP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY
Abello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY. Journal Of Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.Peer-Reviewed Original Research
2018
MP18-20 EX-VIVO TARGETING OF UPPER TRACT UROTHELIAL CARCINOMA USING A NOVEL PHLIP – ICG CONSTRUCT
Brito J, Golijanin B, Pereira J, Amin A, Golijanin D. MP18-20 EX-VIVO TARGETING OF UPPER TRACT UROTHELIAL CARCINOMA USING A NOVEL PHLIP – ICG CONSTRUCT. Journal Of Urology 2018, 199: e221. DOI: 10.1016/j.juro.2018.02.596.Peer-Reviewed Original Research
2017
69 Novel ex vivo endoscopic near infrared fluorescence imaging method using pHLIP®/ICG in patients undergoing radical cystectomy for urothelial carcinoma of the bladder
Brito J, Golijanin B, Tran T, Moshnikova A, Gershman B, Engelman D, Reshetnyak Y, Andreev O, Amin A, Golijanin D. 69 Novel ex vivo endoscopic near infrared fluorescence imaging method using pHLIP®/ICG in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. European Urology Open Science 2017, 16: e116-e117. DOI: 10.1016/s1569-9056(17)30136-7.Peer-Reviewed Original Research
2016
Presence and percentage of type 2 papillary RCC in mixed (type 1 and type 2) papillary renal cell carcinoma does not portend worse prognosis in patients treated by partial/radical nephrectomy in non-metastatic disease.
Leone A, Diorio G, Brito J, Zargar K, Pareek G, Renzulli J, Dickinson S, Amin A, Sexton W, Spiess P, Poch M, Golijanin D. Presence and percentage of type 2 papillary RCC in mixed (type 1 and type 2) papillary renal cell carcinoma does not portend worse prognosis in patients treated by partial/radical nephrectomy in non-metastatic disease. Journal Of Clinical Oncology 2016, 34: e16126-e16126. DOI: 10.1200/jco.2016.34.15_suppl.e16126.Peer-Reviewed Original ResearchPD03-05 UPSTAGING IN RADICAL PROSTATECTOMY IN THE POST-PSA ERA: AN EFFECT OF DELAYED DIAGNOSIS OR BETTER PATIENT SELECTION?
Rotker K, Brito J, Edmund L, Matoso A, Renzulli J. PD03-05 UPSTAGING IN RADICAL PROSTATECTOMY IN THE POST-PSA ERA: AN EFFECT OF DELAYED DIAGNOSIS OR BETTER PATIENT SELECTION? Journal Of Urology 2016, 195: e57-e58. DOI: 10.1016/j.juro.2016.02.2093.Peer-Reviewed Original ResearchMP36-18 HIGH-RISK HPV SUBTYPES IN SQUAMOUS CELL CARCINOMA OF THE SCROTUM
Brito J, Rotker K, Lepe M, Quddus M, Manna P, Epstein J, Matoso A, Renzulli J. MP36-18 HIGH-RISK HPV SUBTYPES IN SQUAMOUS CELL CARCINOMA OF THE SCROTUM. Journal Of Urology 2016, 195: e496. DOI: 10.1016/j.juro.2016.02.1652.Peer-Reviewed Original ResearchMP49-20 EX VIVO FLUORESCENCE IMAGING OF UROTHELIAL CARCINOMA IN HUMAN BLADDERS TARGETED BY ICG-PHLIP
Brito J, Golijanin J, Tran T, Andreev G, Reshetnyak Y, Amin A, Golijanin D. MP49-20 EX VIVO FLUORESCENCE IMAGING OF UROTHELIAL CARCINOMA IN HUMAN BLADDERS TARGETED BY ICG-PHLIP. Journal Of Urology 2016, 195: e671-e672. DOI: 10.1016/j.juro.2016.02.433.Peer-Reviewed Original Research
2015
MP57-16 ANTIPLATELET/ANTICOAGULATION THERAPY DOES NOT INCREASE IMMEDIATE COMPLICATIONS IN PATIENTS UNDERGOING ROBOTIC PARTIAL NEPHRECTOMY (RPN)
Leone A, Turini G, Brito J, Tran T, Renzulli J, Pareek G, Golijanin D. MP57-16 ANTIPLATELET/ANTICOAGULATION THERAPY DOES NOT INCREASE IMMEDIATE COMPLICATIONS IN PATIENTS UNDERGOING ROBOTIC PARTIAL NEPHRECTOMY (RPN). Journal Of Urology 2015, 193: e695-e696. DOI: 10.1016/j.juro.2015.02.2004.Peer-Reviewed Original Research